A phase III trial of evogliptin for type 2 diabetes

Trial Profile

A phase III trial of evogliptin for type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Evogliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Oct 2015 New trial record
    • 02 Oct 2015 According to a Dong-A St media release, the South Korean MFDS (Ministry of Food and Drug Safety) has approved the NDA of SUGANON (DA-1229, Evogliptin 5mg tablet) for type 2 diabetes mellitus.
    • 31 Dec 2014 According to the company Annual Report 2014, a New Drug Application was filed in 2015 for evogliptin to the South Korean MFDS (Ministry of Food and Drug Safety).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top